With 54 biosimilar drugs approved by the FDA and more in the pipeline, pharmacy benefit brokers are navigating a relatively new area and faced with decisions that impact plan performance.
- Should biosimilars be on plan formularies?
- Is there any difference in how effective they are?
- Can they be a game changer for employer cost savings and lower out-of-pocket costs for plan members?
